Journal of the Autonomic Nervous System
[]Rilmenidine-labelled imidazoline-receptor binding sites co-localize with []2-(benzofuranyl)-2-imidazoline-labelled imidazoline-receptor binding sites and monoamine oxidase-B in rabbit, but not rat, kidney
Introduction
Antihypertensive agents such as rilmenidine and clonidine are reported to act via α2-adrenoceptors and/or imidazoline receptor binding sites (I-RBS). []Rilmenidine has been reported to label both α2A-adrenoceptors and novel I2B like-RBS throughout the rat central nervous system (King et al., 1992, King et al., 1995a). High densities of []rilmenidine-labelled I2B like-RBS were located in the arcuate nucleus, ependymal cell layer of the third ventricle, interpeduncular nucleus and pineal gland (King et al., 1995a), regions shown to also contain high relative densities of []idazoxan-labelled I2-RBS (Mallard et al., 1992), as well as MAO-B enzymes (Willoughby et al., 1988; Saura et al., 1992). In addition, in situ hybridization histochemistry studies reveal a high density of MAO-B mRNA localized in these regions of the rat brain (Luque et al., 1995).
Monoamine oxidase (MAO) enzymes are located on the outer mitochondrial membrane and are responsible for the deamination of biogenic and trace amines. Substrate selectivity and inhibitor sensitivity form the basis of classification of two isoforms of the enzyme. MAO-A is selectively inhibited by nanomolar concentrations of clorgyline, and MAO-B by l-deprenyl. The strong association of I2-RBS and MAO enzymes is well documented in that they share common subcellular localization in human and rabbit kidney and liver (Lachaud-Pettiti et al., 1991; Tesson et al., 1991); chronic treatment of rats with MAO inhibitors decreases I2-RBS densities in rat brain and liver (Olmos et al., 1993; Alemany et al., 1995, Alemany et al., 1997); I2-RBS and MAO-B densities positively correlate with aging in human brain (Sastre and Garcı́a-Sevilla, 1993); elevated levels of MAO enzyme activity and I2-RBS occur in Alzheimic brain (Ruiz et al., 1993; Saura et al., 1994); MAO and I2-RBS have high (micro)sequence homology; and expression of MAO-A and -B in yeast results in a co-expression of I2-RBS (Tesson et al., 1995). However, biochemical studies have revealed photoaffinity/radioligand labelling of I2-RBS was unaffected by MAO inhibitors such as pargyline (Lanier et al., 1995) and that MAO activity was inhibited by some imidazoline derivatives, but not idazoxan itself (Carpéné et al., 1995), suggesting the location of I2-RBS at a site distinct from the catalytic site on MAO enzyme molecules.
In light of these findings and previous studies in our laboratory on the distribution and characterization of []rilmenidine-labelled I-RBS in rat kidney (King et al., 1995b) and I2-RBS labelled by the selective ligand []2-BFI in rabbit kidney membranes (Hosseini et al., 1997), the aim of this study was to directly compare the regional distribution of []rilmenidine- and []2-BFI-labelled I-RBS with that of []RO41-1049- and []RO19-6327-labelled MAO-A and MAO-B enzymes in rat and rabbit kidney to determine whether []rilmenidine- and/or []2-BFI label I-RBS that are independent of MAO isoenzymes.
Section snippets
Animals
Ethical approval was granted for all procedures associated with these studies by the Austin and Repatriation Medical Centre Animal Welfare Committee and experiments were carried out according to guidelines issued by the National Health and Medical Research Council of Australia. Dutch rabbits and Wistar–Kyoto rats were obtained from the Biological Research Laboratories at the Austin and Repatriation Medical Centre. Male Wistar–Kyoto rats (250 g) were stunned and killed by decapitation. Rabbits
Rat
In rat kidney, []rilmenidine labelled a high density of non-adrenergic binding sites in the cortex and outer stripe of rat kidney (Fig. 1A, B) that were not inhibited by the imidazole derivatives, imidazole-4-acetic acid and cimetidine, or the imidazoline, idazoxan (Table 1). In contrast, very low levels of []2-BFI binding were present in the rat kidney (Fig. 1D, E; Table 2). []RO41-1049 labelled a high density of presumed MAO-A in all regions of the rat kidney (Fig. 1G; Table 3), while
Discussion
The present study reports the comparative localization and relative densities of I-RBS labelled by []rilmenidine and []2-BFI, with MAO-A and -B enzymes labelled by the highly selective radioligands, []RO41-1049 and []RO19-6327, in rat and rabbit kidney. Results demonstrate that species-dependent differences exist in the distribution and densities of both I-RBS and MAO isoenzymes and provide further evidence that I2-RBS are closely associated with MAO enzymes and that []rilmenidine
Conclusion
In summary, the current findings suggest that []rilmenidine labels a high density of novel I-RBS in rat kidney and multiple I-RBS in rabbit kidney that are presumably localized to the proximal tubules in the outer stripe and medullary rays in the cortex. The pattern of []rilmenidine binding is unlike the distribution pattern of MAO-A and -B in rat kidney, demonstrating []rilmenidine-labelled sites are predominantly not associated with either enzyme in this species. Therefore, the rat
Acknowledgements
This work was supported by grants from the National Health and Medical Research Council of Australia, and the Austin Hospital Medical Research Foundation. S.S. was the recipient of an Aichi Medical University Research Scholarship and A.R.H. was the recipient of a scholarship from the Ministry of Health and Medical Education, Iran.
References (30)
- et al.
Pharmacology and subcellular distribution of rilmenidine binding sites in rat brain
J. Auton. Nerv. Syst.
(1998) - et al.
α2-Adrenoceptor and catecholamine-insensitive binding sites for []rilmenidine in membranes from rat cerebral cortex
Eur. J. Pharmacol.
(1992) - et al.
Quantitative autoradiographic localization in rat brain of α2-adrenergic and non-adrenergic I-receptor binding sites labelled by []rilmenidine
Brain Res.
(1995) - et al.
Differential characteristics and localisation of []oxazoline and []imidazoline binding sites in rat kidney
Eur. J. Pharmacol.
(1995) - et al.
Imidazoline–guanidinium and α2-adrenergic binding sites in basolateral membranes from human kidney
Eur. J. Pharmacol.
(1991) - et al.
[]2-2(2-benzofuranyl)imidazoline, a new selective high affinity radioligand for the study of rabbit brain imidazoline I2 receptors
Eur. J. Pharmacol.
(1996) - et al.
Are there multiple imidazoline binding sites?
Trends Pharmacol. Sci.
(1989) - et al.
Imidazoline receptors: Qualitative structure-activity relationships and discovery of tracizoline and benazoline. Two ligands with high affinity and unprecedented selectivity
Bioorg. Med. Chem.
(1997) - et al.
Non-adrenoceptor []idazoxan binding sites (I2-imidazoline sites) are increased in postmortem brain from patients with Alzheimer's disease
Neurosci. Lett.
(1993) - et al.
Increased monoamine oxidase B activity in plaque-associated astrocytes of Alzheimer brains revealed by quantitative enzyme radioautography
Neuroscience
(1994)
Localization of I2-imidazoline binding sites on monoamine oxidases
J. Biol. Chem.
Subcellular distribution of imidazoline–guanidinium-receptive sites in human and rabbit liver. Major localization to the mitochondrial outer membrane
J. Biol. Chem.
The effects of phenelzine and other monoamine oxidase inhibitor antidepressants on brain and liver I2 imidazoline-preferring receptors
Br. J. Pharmacol.
Labelling of I2B-imidazoline receptor by []2-(2-benzofuranyl)-2-imidazoline (2-BFI) in rat brain and liver: characterization, regulation and relation to monoamine oxidase enzymes
Naunyn-Schmiedeberg's Arch. Pharmacol.
Inhibition of amine oxidase activity by derivatives that recognise imidazoline I2 sites
J. Pharmacol. Exp. Ther.
Cited by (5)
Recent advances in imidazoline receptor research: Ligands-localization and isolation-signaling-functional and clinical studies
1998, Journal of the Autonomic Nervous SystemImidazoline receptor system: The past, the present, and the future
2020, Pharmacological ReviewsIdentification of imidazoline-receptor binding sites in cortex and medulla of the bovine adrenal gland. Colocalization with MAO-A and MAO-B
1999, Annals of the New York Academy of Sciences<sup>3</sup>H[2-(2-benzofuranyl)-2-imidazoline] (BFI) binding in human platelets: Modulation by tranylcypromine
1999, Naunyn-Schmiedeberg's Archives of Pharmacology
- 1
Present address: Owari Asahi Clinic, 2505-1 Harada, Higashi Daidoucho, Owari Asahi, Aichi 488, Japan.
- 2
Present address: PO Box 358, Malek Ashtar Post Office, Tehran 13475, Iran.